Youngman Oh, M.S., Ph.D.
Massey Cancer Center research program membership
Department of Pathology,
School of Medicine
PhD, Stanford University (1993)
MS, Eastern Michigan University (1987)
My laboratory has discovered an entirely distinct anti-tumor and anti-metastatic signaling pathway through a new class of cell death receptor, known as TMEM219. We have further obtained two monoclonal antibodies (mAbs) that activate the TMEM219 receptor, so-called "agonistic antibodies." Currently, my laboratory focuses on therapeutic potential of those TMEM219 mAbs as a monotherapy or a combinational therapy with chemodrugs and immune checkpoint inhibitors in breast, lung, colon, and pancreatic cancer and AML.
Disease focus of research
Breast, Hematologic Malignancies, Prostate, Colorectal, Hepatic, Pancreatic
Angiogenesis,Animal models,Apoptosis,Biomarkers,Cancer cell biology,Cancer therapy resistance,Cell signaling,Drug discovery,Immunotherapy,Inflammation,Obesity,Signal transduction,Targeted therapies,Translational science
Published research (during tenure as a Massey Cancer Center member)
Search In PubMed